AbbVie Inc.
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Ozurdex (dexamethasone intravitreal implant) by Year
Ozurdex (dexamethasone intravitreal implant) — International reported growth YoY (%) (%)
AbbVie Ozurdex (dexamethasone intravitreal implant): 3.7% in FY2025, down 4.6 pts from a year earlier.
Where the FY2025 figure comes from
“|| Ozurdex | 124 | 369 | 493 | (10.1) | 3.7 | (0.2) | 3.0 | (0.7)”
Source: Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Reported in Form 8-K Key Product Revenues Schedule.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Ozurdex (dexamethasone intravitreal implant) — International reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3.7% | -4.6 pts | Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗ |
| FY2024 | Dec 31, 2024 | 8.3% | -5.7 pts | Form 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗ |
| FY2023 | Dec 31, 2023 | 14.0% | – | Form 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗ |
Cite this data
StockData. (2026). AbbVie Ozurdex (dexamethasone intravitreal implant) (%), annual FY2023–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/ozurdex-intl-rep-yoy
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.